Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Another Opinion - Understanding the role of Jazz Pharma's Vyxeos (cytarabine and daunorubicin liposome for injection) in the AML treatment space

Ticker(s): JAZZ

Who's the expert?

Name: Dr Douglas Smith - MD

Institution: Johns Hopkins University

Bio:

  • Involved in the care of several hundred patients with AML at various stages of treatment (active and follow-up) and include newly diagnosed pts, relapsed, refractory, pre and post BMT
  • Manages the leukemia clinical trials portfolio for AML for John Hopkin's large academic practice
  • Confirmed very strong knowledge of clinical data for AML treatments

Interview Questions
Q1.

Please describe your current practice. How many patients do you currently treat with AML?

Added By: c_admin
Q2.

How do you stratify your AML patients  (ex.by young patients versus greater than 60, patients who are fit, or unfit). How you're currently treating those patient groups?

Added By: c_admin
Q3.

Do you think doctors will restrict usage of Vyxeos to the trial population (older than 60) or will they use it with younger patients as well?

Added By: c_admin
Q4.

What do you think was driving the survival benefit in the Vyxeos trial?

Added By: c_admin
Q5.

What are some of the unanswered questions in your mind in terms of the granularity around that data? What would you like to see and learn when the full data is published?

Added By: c_admin
Q6.

On a scale of 1-10, where would you rate your level of excitement for Vyxeos with 10 being very excited?

Added By: c_admin
Q7.

Is there anything else that you think is relevant in terms of treatments on the horizon that you're very excited about?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.